1. Show article details.

    Some 'cheap' biotech stocks that could be buyout targets, RBC says

    MarketWatch – 1:31 PM ET 01/25/2016

    Shares of Arbutus Biopharma (ABUS), SteadyMed (STDY) and Endocyte (ECYT) are trading below cash value. The recent carnage in biotechnology stocks has created a number of opportunities for investors to buy into the sector on the cheap, according to RBC Capital. Analysts at RBC have compiled a list of biotech stocks trading below, or just slightly above cash levels, which could signal a "floor" for the stocks, or make them potential buyout targets for value investors.

  2. Show article details.

    VIVUS, Inc. Announces Intent to Reacquire U.S. and Canadian Rights for Stendra(R) (Avanafil)

    Market Wire – 1:00 PM ET 12/31/2015

    12/31/15 -- VIVUS (VVUS), Inc.  , announced today that it has been notified by Auxilium Pharmaceuticals, Inc., a subsidiary of Endo International, plc., of Auxilium's intention to return the U.S. and Canadian commercial rights for STENDRA® to VIVUS (VVUS). "We are excited to reacquire the U.S. and Canadian commercial rights for STENDRA.

  3. Show article details.

    A New Take On New Year's And Chronic Weight Management: Smart Changes™ Program Combines Positive Lifestyle Changes With Prescription Medication For Weight Loss

    PR Newswire – 9:00 AM ET 12/29/2015

    MOUNTAIN VIEW, Calif. Adults who are obese or overweightii who made New Year's resolutionsiii to lose weight reported making an average of eight attempts, and an average of six were unsuccessful.

  4. Show article details.

    VIVUS Reports Third Quarter 2015 Financial Results

    Market Wire – 4:05 PM ET 11/04/2015

    11/04/15 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the third quarter ended September 30, 2015.

  5. Show article details.

    VIVUS Announces Qsymia Presentations at Obesity Week 2015

    Market Wire – 7:00 AM ET 11/03/2015

    11/03/15 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing Qsymia® capsules CIV for the treatment of obesity, today announced the following presentations at Obesity Week 2015, Los Angeles Convention Center.

  6. Show article details.

    VIVUS Announces Date of Third Quarter 2015 Update and Financial Results Teleconference

    GlobeNewswire – 7:00 AM ET 10/28/2015

    VIVUS, Inc. (VVUS) today announced that it will provide an update and report financial results for the third quarter ended September 30, 2015 after the NASDAQ Market closes on Wednesday, November 4, 2015. Date: November 4, 2015. Time: 4:30PM ET Listen via Internet: http://ir.vivus.com/   Schedule this webcast into MS-Outlook calendar: http://apps.shareholder.com/PNWOutlook/t.aspx?m=70875&k=8DE79789.

  7. Show article details.

    VIVUS, Inc. Board of Directors Expresses No Opinion and Remains Neutral Toward Icahn Group's Unsolicited Offer to Purchase 4.50% Convertible Senior Notes

    Market Wire – 4:05 PM ET 09/22/2015

    09/22/15 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea and sexual health, announced today that its Board of Directors has determined that it expresses no opinion and remains neutral toward the unsolicited tender offer by IEH Biopharma LLC, a Delaware limited liability company and w...


Today's and Upcoming Events

  • Feb

    VVUS to announce Q4 earnings After Market (Unconfirmed)

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2016

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.